Tamoxifen

BreastfeedingPediatric
  • TRADE NAMES: Apo-Tamox; Bilim; Istubol; Kessar; Mamofen; Nolvadex (AstraZeneca); Novofen; Tamaxin; Tamofen; Tamoxan; Taxus; Valodex
  • INDICATIONS: Advanced breast cancer
  • CLASS: Selective estrogen receptor modulator (SERM)
  • HALF-LIFE: 5–7 days
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Anastrozole, Bexarotene, Cinacalcet, Delavirdine, Droperidol, Duloxetine, Gadobenate, Paroxetine Hydrochloride, Rifapentine, Terbinafine, Tipranavir

PREGNANCY CATEGORY: D

Our database has 128 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
HAIR
NAILS
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
GENITOURINARY
HEMATOLOGIC
LOCAL
NEUROMUSCULAR/SKELETAL
OCULAR
RESPIRATORY
OTHER


Page last updated 07/31/2019

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top